Development of TRAIL-R2 synthetic trimer agonists for cancer therapy

被引：0
|
作者：
Angell, Y. M.
Frederick, B. T.
Green, J.
Schatz, P. J.
Whitehorn, E. A.
Wright, K. L.
Holmes, C. H.
机构：
[1] Affymax Inc, Dept Chem, Palo Alto, CA 94304 USA
[2] Affymax Inc, Dept Biol, Palo Alto, CA 94304 USA
来源：
BIOPOLYMERS | 2007年 / 88卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：532 / 532
页数：1
相关论文
共 50 条
  • [41] TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
    Tamada, Taro
    Shinmi, Daisuke
    Ikeda, Masahiro
    Yonezawa, Yasushi
    Kataoka, Shiro
    Kuroki, Ryota
    Mori, Eiji
    Motoki, Kazuhiro
    SCIENTIFIC REPORTS, 2015, 5
  • [42] TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
    Bellail, Anita C.
    Qi, Ling
    Mulligan, Patrick
    Chhabra, Vaninder
    Hao, Chunhai
    REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (01) : 34 - 41
  • [43] Meta analysis for association of TRAIL DR4/TRAIL-R1 and DR5/TRAIL-R2 with hepatocelluar carcinoma prognosis
    Zhang, Lu
    Chen, Xiang-Jun
    He, Da
    Zhou, Tao-You
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (09): : 12995 - 13002
  • [44] Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 is not necessary for but contributes to sensitization of primary human glioma cells to TRAIL
    Koschny, Ronald
    Sykora, Jaromir
    Walczak, Henning
    Ganten, Tom M.
    Haas, Tobias L.
    Sprick, Martin R.
    Holland, Heidrum
    Ahnert, Peter
    Krupp, Wolfgang
    Meixensberger, Juergen
    Bauer, Manfred
    CLINICAL CANCER RESEARCH, 2007, 13 (21) : 6541 - 6542
  • [45] Frequent expression of TRAIL-R2 in human breast tumors revealed by antibody proteomics technology
    Nagano, Z. Kazuya
    Yamashita, Takuya
    Okamura, Takayuki
    Watanabe, Takanobu
    Kanasaki, Souichiro
    Abe, Yasuhiro
    Kamada, Haruhiko
    Tsunoda, Shin-ichi
    Tsutsumi, Yasuo
    CYTOKINE, 2009, 48 (1-2) : 54 - 55
  • [46] Discovery and optimization of a TRAIL R2 agonist for cancer therapy
    Angell, Yvonne M.
    Bhandari, Ashok
    Chakrabarti, Anjan
    De Francisco, M. Nuria
    Duguay, Amy N.
    Frederick, Brian T.
    Leu, Karen
    Leuther, Kerstin
    Li, Xianfeng
    Penta, Kalyani
    Piplani, Sunila
    Sana, Reuben
    Whitehorn, Erik A.
    Schatz, Pete J.
    Yin, Kevin
    Holmes, Christopher P.
    UNDERSTANDING BIOLOGY USING PEPTIDES, 2006, : 405 - +
  • [47] Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2
    J Li
    M G Anderson
    L A Tucker
    Y Shen
    K B Glaser
    O J Shah
    Cell Death & Differentiation, 2009, 16 : 498 - 511
  • [48] Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2
    Li, J.
    Anderson, M. G.
    Tucker, L. A.
    Shen, Y.
    Glaser, K. B.
    Shah, O. J.
    CELL DEATH AND DIFFERENTIATION, 2009, 16 (03): : 498 - 511
  • [49] Discovery and Optimization of a TRAIL R2 Agonist for Cancer Therapy
    Angell, Yvonne M.
    Bhandari, Ashok
    De Francisco, M. Nuria
    Frederick, Brian T.
    Green, Jennifer M.
    Leu, Karen
    Leuther, Kerstin
    Sana, Reuben
    Schatz, Peter J.
    Whitehorn, Erik A.
    Wright, Kathy
    Holmes, Christopher P.
    PEPTIDES FOR YOUTH, 2009, 611 : 101 - 103
  • [50] Requirement of both isoforms of TRAIL-R2 (DR5) in death receptor signaling
    Peters, Kristi
    Yang, Ke
    DeVecchio, Jennifer
    Humphreys, Robin
    Houghton, Janet
    CANCER RESEARCH, 2009, 69
12345